

# CITATION REPORT

List of articles citing

## Clinical pharmacokinetics of halofantrine

DOI: 10.2165/00003088-199427020-00003  
Clinical Pharmacokinetics, 1994, 27, 104-19.

**Source:** <https://exaly.com/paper-pdf/25418532/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
69	Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations. <i>Clinical Pharmacokinetics</i> , <b>1994</b> , 27, 150-65	6.2	19
68	Antiprotozoal drugs. <i>Side Effects of Drugs Annual</i> , <b>1995</b> , 262-272	0.2	
67	New solid-phase extraction for an improved high-performance liquid chromatographic procedure for the quantitation of halofantrine and monodesbutylhalofantrine in blood or plasma. <i>Biomedical Applications</i> , <b>1995</b> , 668, 315-21		12
66	A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>1995</b> , 13, 911-8	3.5	21
65	The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum. <i>British Journal of Clinical Pharmacology</i> , <b>1995</b> , 39, 519-26	3.8	29
64	Evaluation of the safety and efficacy of micronized halofantrine in the treatment of semi-immune patients with acute, Plasmodium falciparum malaria. <i>Annals of Tropical Medicine and Parasitology</i> , <b>1996</b> , 90, 461-6		2
63	Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1997</b> , 29, 207-8		16
62	Antiprotozoal drugs. <i>Side Effects of Drugs Annual</i> , <b>1997</b> , 20, 257-268	0.2	
61	Is halofantrine still advisable in malaria attacks?. <i>Annals of Tropical Medicine and Parasitology</i> , <b>1997</b> , 91, 867-873		5
60	X-ray crystal structure of the antimalarial agent (-)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1997</b> , 41, 791-4	5.9	10
59	Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. <i>British Journal of Clinical Pharmacology</i> , <b>1998</b> , 45, 315-7	3.8	32
58	Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. <i>International Journal of Pharmaceutics</i> , <b>1998</b> , 167, 155-164	6.5	277
57	In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. <i>Xenobiotica</i> , <b>1999</b> , 29, 595-601	2	1
56	Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. <i>Journal of Pharmaceutical Sciences</i> , <b>1999</b> , 88, 185-90	3.9	19
55	Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons. <i>Biopharmaceutics and Drug Disposition</i> , <b>1999</b> , 20, 165-9	1.7	21
54	Les antimalariques: pharmacologie, pharmacocinétique et toxicité chez l'adulte. <i>Médecine Et Maladies Infectieuses</i> , <b>1999</b> , 29, S229-S248	4	4
53	La toxicité cardiaque des antipaludéens. <i>Médecine Et Maladies Infectieuses</i> , <b>1999</b> , 29, S316-S325	4	2

52	Effects of food on clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , <b>1999</b> , 37, 213-55	6.2	249
51	Clinical Pharmacokinetics of Artemether and Lumefantrine (Riamet®). <i>Clinical Drug Investigation</i> , <b>1999</b> , 18, 467-480	3.2	59
50	The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France. <i>International Journal of Antimicrobial Agents</i> , <b>1999</b> , 12, 159-69	14.3	40
49	Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. <i>Biopharmaceutics and Drug Disposition</i> , <b>2000</b> , 21, 365-71	1.7	17
48	The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment. <i>International Journal of Pharmaceutics</i> , <b>2000</b> , 205, 65-78	6.5	65
47	Pharmacokinetic interaction trial between co-artemether and mefloquine. <i>European Journal of Pharmaceutical Sciences</i> , <b>2000</b> , 10, 141-51	5.1	56
46	The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins. <i>Pharmaceutical Research</i> , <b>2000</b> , 17, 427-31	4.5	23
45	Drugs for malaria. <i>Seminars in Pediatric Infectious Diseases</i> , <b>2000</b> , 11, 202-212		4
44	Short-term adverse effects in humans of ingested mineral oils, their additives and possible contaminants--a review. <i>Human and Experimental Toxicology</i> , <b>2000</b> , 19, 158-72	3.4	13
43	Pharmacokinetic interactions of antimalarial agents. <i>Clinical Pharmacokinetics</i> , <b>2001</b> , 40, 343-73	6.2	93
42	Halofantrine-phospholipid interactions: monolayer studies. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2001</b> , 49, 871-6	1.9	8
41	Effect of the antimalarial drug halofantrine in the long QT syndrome due to a mutation of the cardiac sodium channel gene SCN5A. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 909-11	3	20
40	Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding. <i>Biopharmaceutics and Drug Disposition</i> , <b>2002</b> , 23, 9-15	1.7	15
39	A new high-performance liquid chromatography (HPLC) method for the analysis of halofantrine (HF) in pharmaceuticals. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2002</b> , 29, 901-8	3.5	3
38	Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. <i>Clinical Pharmacokinetics</i> , <b>2003</b> , 42, 1359-82	6.2	79
37	Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 58, 52-5	3.8	9
36	Antimalarial drug toxicity: a review. <i>Drug Safety</i> , <b>2004</b> , 27, 25-61	5.1	335
35	Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 1222-8	5.9	82

34	[Chiral switch: towards a better benefit-risk ratio?]. <i>Therapie</i> , <b>2004</b> , 59, 625-8	3.8	1
33	Assessment of safety of the major antimalarial drugs. <i>Expert Opinion on Drug Safety</i> , <b>2007</b> , 6, 505-21	4.1	12
32	Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. <i>Tohoku Journal of Experimental Medicine</i> , <b>2007</b> , 211, 99-113	2.4	58
31	Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 203-6	3.2	5
30	The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: evidence of tissue-specific enantioselectivity in microsomal metabolism. <i>Chirality</i> , <b>2007</b> , 19, 22-33	2.1	9
29	Proarrhythmic potential of antimicrobial agents. <i>Infection</i> , <b>2008</b> , 36, 194-206	5.8	56
28	Effect of bile and lipids on the stereoselective metabolism of halofantrine by rat everted-intestinal sacs. <i>Chirality</i> , <b>2010</b> , 22, 275-83	2.1	7
27	Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. <i>Malaria Journal</i> , <b>2009</b> , 8, 289	3.6	48
26	Pharmacodynamics of antimalarial chemotherapy. <i>Expert Review of Clinical Pharmacology</i> , <b>2009</b> , 2, 491-518	3.8	4
25	Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model. <i>Journal of Pharmacy and Pharmacology</i> , <b>2004</b> , 56, 69-77	4.8	48
24	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. <i>Journal of Pharmacy and Pharmacology</i> , <b>1999</b> , 51, 419-26	4.8	28
23	Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats. <i>British Journal of Pharmacology</i> , <b>2010</b> , 161, 1427-40	8.6	10
22	Chemotherapeutic interaction between <i>Khaya grandifoliola</i> (WELW) CDC stem bark extract and two anti-malarial drugs in mice. <i>Tropical Journal of Obstetrics and Gynaecology</i> , <b>2010</b> , 7, 370-6	0.3	7
21	Antiparasitic agents. <b>2010</b> , 1490-1507		0
20	Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. <i>Journal of Pharmacy and Pharmacology</i> , <b>1996</b> , 48, 723-8	4.8	6
19	Submicron oil-in-water emulsion formulations for mefloquine and halofantrine: effect of electric-charge inducers on antimalarial activity in mice. <i>Journal of Pharmacy and Pharmacology</i> , <b>1998</b> , 50, 1221-5	4.8	6
18	Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria. <i>Journal of Pharmacy and Pharmacology</i> , <b>2012</b> , 64, 1603-13	4.8	3
17	Extrahepatic Drug-Metabolizing Enzymes and Their Significance. <b>2012</b> , 1		3

16	Rational formulation development and in vitro assessment of SMEDDS for oral delivery of poorly water soluble drugs. <i>European Journal of Pharmaceutical Sciences</i> , <b>2012</b> , 46, 508-15	5.1	35
15	Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against <i>Schistosoma mansoni</i> in mice. <i>Korean Journal of Parasitology</i> , <b>2013</b> , 51, 165-75	1.7	8
14	Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. <i>Drug Metabolism Reviews</i> , <b>2015</b> , 47, 291-319	7	10
13	Malaria treatment using novel nano-based drug delivery systems. <i>Journal of Drug Targeting</i> , <b>2017</b> , 25, 567-581	5.4	20
12	Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	25
11	Antiparasitic Agents. <b>2017</b> , 1345-1372.e2		9
10	Chiral Method by Normal Phase HPLC/DV for Quantitation of Lumefantrine Enantiomers in Tablet Formulations. <i>Chromatographia</i> , <b>2019</b> , 82, 1759-1766	2.1	1
9	Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	57
8	Antimalarial Agents. <b>2003</b> , 919-1031		2
7	Agents Active against Parasites and Pneumocystis. <b>2010</b> , 631-668		1
6	Antiprotozoal agents: How have they changed over a decade?. <i>Archiv Der Pharmazie</i> , <b>2021</b> , e2100338	4.3	1
5	Halofantrine. <b>2007</b> , 1-4		
4	Cellular Mechanisms, Molecular Targets, and Structure-Function Relationships in Drug-Induced Arrhythmias: Antihistamines, Psychoactive Drugs, and Antimicrobial Agents. 47-96		
3	Halofantrine. <b>2010</b> , 2036-2041		
2	Expression of Two Key Enzymes of Artemisinin Biosynthesis FPS and ADS genes in. <i>Advanced Pharmaceutical Bulletin</i> , <b>2021</b> , 11, 181-187	4.5	
1	Expression of Two Key Enzymes of Artemisinin Biosynthesis FPS and ADS genes in <i>Saccharomyces cerevisiae</i> . <i>Advanced Pharmaceutical Bulletin</i> , <b>2021</b> , 11, 181-187	4.5	2